Aurobindo Pharma informs about company updates

30 Jan 2020 Evaluate

Further to intimations dated 7th & 11th October, 2019 with regard to the USFDA inspection of Unit VII, an oral solids formulation manufacturing facility of the Company, Aurobindo Pharma has informed that the Company has received a letter from the USFDA classifying the inspection conducted at the aforesaid facility as Official Action Indicated (OAI). This OAI classification will not have any material impact on the existing revenues or the supplies to its US business at this juncture. The Company will work closely with the regulator to comprehensively address the issues. 

The above information is a part of company’s filings submitted to BSE.

Aurobindo Pharma Share Price

1217.45 -6.20 (-0.51%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×